Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two do...
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
About this item
Full title
Author / Creator
DeAngelo, D J , Spencer, A , Bhalla, K N , Prince, H M , Fischer, T , Kindler, T , Giles, F J , Scott, J W , Parker, K , Liu, A , Woo, M , Atadja, P , Mishra, K K and Ottmann, O G
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week o...
Alternative Titles
Full title
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1427005056
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1427005056
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2013.38
